The individual response to DST or CRH infusion test could be determined by genetic factors, such as NR3C1 and FKBP5. Altered expression of these genes, resulting from polymorphisms (FKBP5) or epigenetic modifications (NR3C1), seems promising as markers of susceptibility, diagnosis, or treatment outcome in child MDD; however, more studies are needed to verify their usefulness in child and adolescent depression. This evidence concerns the gene CRH and major depressive disorder.